Investigator's Choice Chemotherapy

Phase 3Small molecule

Investigator's Choice Chemotherapy is one of 128 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Breast CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Triple-Negative Breast CancerPhase 3

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Investigator's Choice Chemotherapy

Genmab

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Prolia

Amgen

Preclinical

14 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Spravato

WWim Janssens

Preclinical

2 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT04628494

Phase 3Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT07226752

Q3 2028

Phase 3Recruiting

Triple-Negative Breast Cancer

NCT06732323

Q4 2028

Phase 3Not yet recruiting

Metastatic Colorectal Cancer

NCT05652894

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma3 trials

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting· Genmab logo

Genmab·Phase 3·NCT04628494·484 enrolled

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

Active, not recruiting· Genmab logo

Genmab·Phase 3·NCT07226752·72 enrolled

Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

Completed· Amgen logo

Amgen·Phase 2·NCT03023878·47 enrolled

Metastatic Colorectal Cancer1 trial

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Not yet recruiting·TTaizhou Hanzhong biomedical co. LTD·Phase 3·NCT05652894·190 enrolled

Triple-Negative Breast Cancer1 trial

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06732323·504 enrolled

Breast Cancer1 trial

A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Completed·CCelldex Therapeutics·Phase 2·NCT01156753·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Investigator's Choice Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Investigator's Choice Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Investigator's Choice Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Genmab

Investigator's Choice Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q4 2028

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma3 trials

Metastatic Colorectal Cancer1 trial

Triple-Negative Breast Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News